Evolution of MS lesions to black holes under DNA vaccine treatment
| Autor: | Ludwig Kappos, Joanne Quan, Athina Papadopoulou, Ernst Wilhelm Radue, Robert S. King, Stefanie von Felten, Stefan Traud, Hideki Garren, Amena Rahman, Lawrence Steinman, Gary Cutter |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Pathology Multiple Sclerosis Time Factors Adolescent Placebo Gastroenterology law.invention Young Adult Double-Blind Method Randomized controlled trial law Internal medicine Odds Ratio Vaccines DNA medicine Humans Young adult Analysis of Variance Dose-Response Relationship Drug medicine.diagnostic_test biology business.industry Multiple sclerosis Myelin Basic Protein Magnetic resonance imaging Odds ratio Middle Aged medicine.disease Magnetic Resonance Imaging Dose–response relationship Immunoglobulin M Neurology biology.protein Female Neurology (clinical) Antibody business Follow-Up Studies |
| Popis: | Persistent black holes (PBH) are associated with axonal loss and disability progression in multiple sclerosis (MS). The objective of this work was to determine if BHT-3009, a DNA plasmid-encoding myelin basic protein (MBP), reduces the risk of new lesions becoming PBH, compared to placebo, and to test if pre-treatment serum anti-MBP antibody levels impact on the effect of BHT-3009 treatment. In this retrospective, blinded MRI study, we reviewed MRI scans of 155 MS patients from a double-blind, randomized, phase II trial with three treatment arms (placebo, 0.5 and 1.5 mg BHT-3009). New lesions at weeks 8 and 16 were tracked at week 48 and those appearing as T1-hypointense were classified as PBH. A subset of 46 patients with available pre-treatment serum anti-MBP IgM levels were analyzed separately. Overall, there was no impact of treatment on the risk for PBH. However, there was a significant interaction between anti-MBP antibodies and treatment effect: patients receiving 0.5 mg BHT-3009 showed a reduced risk of PBH with higher antibody levels compared to placebo (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|